Indications for Use of Drug-Coated Balloons in Coronary Intervention: Academic Research Consortium Position Statement.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 41062231.
- Also identified by DOI 10.1016/j.jacc.2025.07.049.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Drug-Coated Balloon (DCB) Academic Research Consortium project originated from the need to overcome the lack of standardization and comparability among studies focusing on drug-coated balloon treatment. The DCB Academic Research Consortium represents a collaborative effort between academic research organizations and the most renowned interventional cardiology societies focusing on percutaneous coronary intervention in Europe, the United States, and Asia. The present consensus document provides a classification of DCB technologies, antiproliferative drugs, and types of elution and coatings. Moreover, by reviewing the available evidence on the use of DCBs for several lesion (restenosis, de novo small and large vessels, bifurcations) and clinical (acute coronary syndromes, diabetes mellitus, multivessel disease, high bleeding risk) settings, it seeks to provide reasonable suggestions for their clinical use. Last, this paper outlines the processes involved in optimal "lesion preparation" before the use of DCBs and the criteria used for assessing results following their use.
Medical subject headings
- Percutaneous Coronary Intervention
- Angioplasty, Balloon, Coronary
- Coronary Artery Disease
- Coated Materials, Biocompatible
- Drug-Eluting Stents